Meyka Pro banner
CBD Global Sciences Inc.

CBD Global Sciences Inc. Fundamental Analysis (CNQ: CBDN.CN)

CBDN.CNCNQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.04
$0.00(0.00%)
Canadian Market is Open · 15:44

CBD Global Sciences Inc. Fundamental Analysis (CNQ: CBDN.CN)

CBD Global Sciences Inc. (CNQ: CBDN.CN) shows weak financial fundamentals with a PE ratio of -0.20, profit margin of -34.69%, and ROE of 1.16%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.02

Areas of Concern

ROE1.16%
Operating Margin-16.41%
Current Ratio0.16
We analyze CBDN.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -3184.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-3184.1/100

We analyze CBDN.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

CBDN.CN struggles to generate sufficient returns from assets.

ROA > 10%
-2.77%

Valuation Score

Excellent

CBDN.CN trades at attractive valuation levels.

PE < 25
-0.20
PEG Ratio < 2
-0.02

Growth Score

Weak

CBDN.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

CBDN.CN shows balanced financial health with some risks.

Debt/Equity < 1
-1.41
Current Ratio > 1
0.16

Profitability Score

Weak

CBDN.CN struggles to sustain strong margins.

ROE > 15%
116.17%
Net Margin ≥ 15%
-34.69%
Positive Free Cash Flow
No

Key Financial Metrics

Is CBDN.CN Expensive or Cheap?

P/E Ratio

CBDN.CN trades at -0.20 times earnings. This suggests potential undervaluation.

-0.20

PEG Ratio

When adjusting for growth, CBDN.CN's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values CBD Global Sciences Inc. at -0.68 times its book value. This may indicate undervaluation.

-0.68

EV/EBITDA

Enterprise value stands at 0.15 times EBITDA. This is generally considered low.

0.15

How Well Does CBDN.CN Make Money?

Net Profit Margin

For every $100 in sales, CBD Global Sciences Inc. keeps $-34.69 as profit after all expenses.

-34.69%

Operating Margin

Core operations generate -16.41 in profit for every $100 in revenue, before interest and taxes.

-16.41%

ROE

Management delivers $1.16 in profit for every $100 of shareholder equity.

1.16%

ROA

CBD Global Sciences Inc. generates $-2.77 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.77%

Following the Money - Real Cash Generation

Operating Cash Flow

CBD Global Sciences Inc. generates limited operating cash flow of $-1.58M, signaling weaker underlying cash strength.

$-1.58M

Free Cash Flow

CBD Global Sciences Inc. generates weak or negative free cash flow of $-1.58M, restricting financial flexibility.

$-1.58M

FCF Per Share

Each share generates $-0.03 in free cash annually.

$-0.03

FCF Yield

CBDN.CN converts -71.03% of its market value into free cash.

-71.03%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.20

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.68

vs 25 benchmark

P/S Ratio

Price to sales ratio

9.63

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.41

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.16

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.16

vs 25 benchmark

ROA

Return on assets percentage

-2.77

vs 25 benchmark

ROCE

Return on capital employed

-76.34

vs 25 benchmark

How CBDN.CN Stacks Against Its Sector Peers

MetricCBDN.CN ValueSector AveragePerformance
P/E Ratio-0.2032.02 Better (Cheaper)
ROE116.17%569.00% Weak
Net Margin-3469.40%29961.00% Weak
Debt/Equity-1.410.53 Strong (Low Leverage)
Current Ratio0.165.67 Weak Liquidity
ROA-276.92%-96.00% (disorted) Weak

CBDN.CN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews CBD Global Sciences Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ